HRP20201764T1 - Upotreba inhibitora miostatina i kombinacijske terapije - Google Patents
Upotreba inhibitora miostatina i kombinacijske terapije Download PDFInfo
- Publication number
- HRP20201764T1 HRP20201764T1 HRP20201764TT HRP20201764T HRP20201764T1 HR P20201764 T1 HRP20201764 T1 HR P20201764T1 HR P20201764T T HRP20201764T T HR P20201764TT HR P20201764 T HRP20201764 T HR P20201764T HR P20201764 T1 HRP20201764 T1 HR P20201764T1
- Authority
- HR
- Croatia
- Prior art keywords
- myostatin
- smn
- inhibitor
- myostatin inhibitor
- use according
- Prior art date
Links
- 102000004472 Myostatin Human genes 0.000 title claims 37
- 108010056852 Myostatin Proteins 0.000 title claims 37
- 239000003112 inhibitor Substances 0.000 title claims 28
- 238000002648 combination therapy Methods 0.000 title 1
- 102100021947 Survival motor neuron protein Human genes 0.000 claims 18
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000003623 enhancer Substances 0.000 claims 4
- 238000012153 long-term therapy Methods 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 101150113275 Smn gene Proteins 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000003698 anagen phase Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 229940124272 protein stabilizer Drugs 0.000 claims 2
- 230000014616 translation Effects 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (15)
1. Inhibitor miostatina koji je selektivan za miostatin za upotrebu u postupku liječenja spinalne mišićne atrofije (SMA) kod subjekta,
pri čemu se selektivni inhibitor miostatina daje u količini efikasnoj za liječenje SMA,
pri čemu je subjekt: (i) na terapiji korektorom za SMN ili je liječen terapijom sa korektorom SMN tijekom šest mjeseci inhibitora miostatina; i (ii) u fazi rasta i/ili ima potrebu za primanjem dugotrajne terapije, gdje dugotrajna terapija po potrebi uključuje održavanje SMA tijekom života, pri čemu je selektivni inhibitor miostatina:
(a) antitijelo, ili njegov dio za vezivanje antigena, koji vezuje pro- ili latentni miostatin, time inhibirajući aktivaciju miostatina; ili
(b) antitijelo, ili njegov dio za vezivanje antigena, koji vezuje zreli miostatin;
i gdje terapija sa korektorom SMN obuhvaća:
i) modifikator spajanja;
ii) zamjenu SMN gena ili genetsku terapiju;
iii) transkripcijski pojačivač za SMN;
iv) pojačivač translacije SMN proteina; ili,
v) stabilizator SMN proteina.
2. Inhibitor miostatina za upotrebu prema zahtjevu 1, gdje je subjekt pedijatrijski subjekt ili mlada odrasla osoba koja još raste i anabolički je aktivna.
3. Inhibitor miostatina za upotrebu prema zahtjevu 1(a), gdje se antitijelo, ili njegov dio za vezivanje antigena, vezuje za prodomen miostatina.
4. Inhibitor miostatina za upotrebu prema zahtjevu 1(a), gdje se antiijtelo, ili njegov dio za vezivanje antigena, ne vezuje za zreli miostatin koji nije povezan sa pro- ili latentnim miostatinom.
5. Inhibitor miostatina za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu korektor SMN je antisens RNK ili mala molekula.
6. Inhibitor miostatina za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu subjekt ima SMA koja ograničava kretanje ili SMA koja ne ograničava kretanje.
7. Inhibitor miostatina za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu subjekt ima dijagnozu tip I SMA, tip II SMA, ili tip III SMA.
8. Inhibitor miostatina za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu subjekt ima osnovni rezultat ≤ 65 Proširene Hammersmith-ove Funkcionalne Motorne Skale prije davanja inhibitora miostatina.
9. Inhibitor miostatina za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu količina efikasna za liječenje SMA je količina koja je efikasna za:
a) odlaganje ili ublažavanje mišićne atrofije;
b) odlaganje gubitka α-motornih neurona;
c) sprječavanje ili odlaganje ekspresije nezrelih mišićnih markera;
d) sprječavanje, ublažavanje ili odlaganje intramuskularnih naslaga masti naznačeno sa masnom zamjenom mišićnog tkiva;
e) povećanje rezultata Proširene Hammersmith-ove Funkcionalne Motorne Skale za ≥ 1 bodova u usporedbi sa netretiranom kontrolnom grupom, ili, za ≥ 1 bodova od osnovnog mjereno prije tretmana;
f) odlaganje napredovanja bolesti prema Proširenoj Hammersmith-ovoj Funkcionalnoj Motornoj Skali tijekom perioda od 12 mjeseci, 24 mjeseca ili 36 mjeseci;
g) povećanje CHOP INTEND rezultata za ≥ 1 bodova u usporedbi sa netretiranom kontrolom; i/ili,
h) povećanje MFM-32 rezultata za najmanje 1 bod u usporedbi sa netretiranom kontrolom.
10. Inhibitor miostatina za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu je inhibitor namijenjen za davanje preko intravenozne injekcije ili infuzije ili preko subkutanozne injekcije.
11. Inhibitor miostatina za upotrebu prema bilo kojem od prethodnih zahtjeva, gdje je inhibitor antitijelo, ili njegov dio za vezivanje antigena, koji:
(a) sadrži šest područja za određivanje komplementarnosti (CDRs): CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, i CDRL3, gdje:
CDRH1 sadrži sekvencu kao što je predstavljena u SEQ ID NO: 1 ili 2;
CDRH2 sadrži sekvencu kao što je predstavljena u SEQ ID NOs: 4 ili 5;
CDRH3 sadrži sekvencu kao što je predstavljena u SEQ ID NO: 10;
CDRL1 sadrži sekvencu kao što je predstavljena u SEQ ID NOs: 12 ili 13;
CDRL2 sadrži sekvencu kao što je predstavljena u SEQ ID NOs: 18 ili 19; i
CDRL3 sadrži sekvencu kao što je predstavljena u SEQ ID NO: 22;
(b) sadrži varijabilnu regiju teškog lanca koji se sastoji iz aminokiselinske sekvence SEQ ID NO:25 i varijabilnu regiju lakog lanca koji se sastoji iz aminokiselinske sekvence SEQ ID NO:31; ili
(c) sadrži teški lanac koji se sastoji iz aminokiselinske sekvence SEQ ID NO:50 i laki lanac koji se sastoji iz aminokiselinske sekvence SEQ ID NO:51.
12. Inhibitor miostatina koji je selektivan za miostatin, korektor SMN, za upotrebu u postupku liječenja spinalne mišićne atrofije (SMA) kod subjekta, pri čemu je subjekt u fazi rasta i/ili ima potrebu za primanjem dugotrajne terapije, pri čemu dugotrajna terapija po potrebi uključuje održavanje SMA tijekom života, pri čemu je selektivni inhibitor miostatina:
(a) antitijelo, ili njegov dio za vezivanje antigena, koji vezuje pro- ili latentni miostatin, time inhibirajući aktivaciju miostatina; ili
(b) antitijelo, ili njegov dio za vezivanje antigena, koji vezuje zreli miostatin, i gdje korektor SMN sadrži:
i) modifikator spajanja
ii) sredstvo za zamjenu SMN gena ili sredstvo za genetsku terapiju;
iii) pojačivač SMN transkripcije;
iv) pojačivač translacije SMN proteina; ili,
v) stabilizator SMN proteina.
13. Inhibitor miostatina i korektor SMN za upotrebu prema zahtjevu 12, pri čemu inhibitor miostatina i korektor SMN su za konkurentno ili serijsko davanje subjektu.
14. Inhibitor miostatina i korektor SMN za upotrebu prema zahtjevu 12 ili zahtjevu 13, pri čemu subjekt prima korektor SMN i inhibitor miostatina tijekom šest mjeseci jednog od drugog.
15. Inhibitor miostatina i korektor SMN za upotrebu prema bilo kojem od zahtjeva 12-14 gdje je subjekt kao što je definirano u zahtjevu 2 ili 6-8; pri čemu je selektivni inhibitor miostatina kao što je definirano u bilo kojem od zahtjeva 3, 4 ili 11; pri čemu korektor SMN je kao što je definirano u zahtjevu 5; pri čemu je selektivni inhibitor miostatina za davanje u količini koja je efikasna za liječenje SMA kako je definirano u zahtjevu 9; i/ili gdje selektivni inhibitor miostatina je za davanje kao što je definirano u zahtjevu 10.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349596P | 2016-06-13 | 2016-06-13 | |
| US201762470157P | 2017-03-10 | 2017-03-10 | |
| US201762486934P | 2017-04-18 | 2017-04-18 | |
| US201762511702P | 2017-05-26 | 2017-05-26 | |
| US201762512254P | 2017-05-30 | 2017-05-30 | |
| PCT/US2017/037332 WO2017218592A1 (en) | 2016-06-13 | 2017-06-13 | Use of myostatin inhibitors and combination therapies |
| EP17732001.7A EP3368069B1 (en) | 2016-06-13 | 2017-06-13 | Use of myostatin inhibitors and combination therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201764T1 true HRP20201764T1 (hr) | 2020-12-25 |
Family
ID=59093642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201764TT HRP20201764T1 (hr) | 2016-06-13 | 2020-10-30 | Upotreba inhibitora miostatina i kombinacijske terapije |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10946036B2 (hr) |
| EP (3) | EP4218804A3 (hr) |
| JP (4) | JP6823167B2 (hr) |
| KR (4) | KR20230028813A (hr) |
| AU (3) | AU2017283546C1 (hr) |
| CL (1) | CL2018003588A1 (hr) |
| CY (1) | CY1123678T1 (hr) |
| DK (1) | DK3368069T3 (hr) |
| ES (1) | ES2830440T3 (hr) |
| HR (1) | HRP20201764T1 (hr) |
| HU (1) | HUE051480T2 (hr) |
| IL (2) | IL301468A (hr) |
| LT (1) | LT3368069T (hr) |
| MY (1) | MY185614A (hr) |
| PE (1) | PE20190205A1 (hr) |
| PT (1) | PT3368069T (hr) |
| RS (1) | RS61090B1 (hr) |
| SI (1) | SI3368069T1 (hr) |
| WO (1) | WO2017218592A1 (hr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| SI2202245T1 (sl) | 2007-09-26 | 2016-10-28 | Chugai Seiyaku Kabushiki Kaisha | Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR |
| CN107488228A (zh) | 2008-04-11 | 2017-12-19 | 中外制药株式会社 | 与多个分子的抗原反复结合的抗原结合分子 |
| RU2658504C9 (ru) | 2010-11-30 | 2018-08-21 | Чугаи Сейяку Кабусики Кайся | Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| EP3783017A1 (en) | 2013-04-02 | 2021-02-24 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
| JP6706617B2 (ja) | 2014-11-06 | 2020-06-10 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | 抗プロ／潜在型−ミオスタチン抗体およびその使用 |
| EP3240804A4 (en) | 2014-12-19 | 2019-01-09 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE |
| EP3816179A3 (en) | 2015-02-05 | 2021-08-04 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant comprising a modified fcrn-binding domain |
| MX2018003196A (es) | 2015-09-15 | 2019-05-16 | Scholar Rock Inc | Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos. |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
| KR20230028813A (ko) | 2016-06-13 | 2023-03-02 | 스칼러 락, 인크. | 미오스타틴 억제제의 용도 및 조합 요법 |
| EA201990017A1 (ru) * | 2016-06-17 | 2019-07-31 | Чугаи Сейяку Кабусики Кайся | Антитела к миостатину и способы их применения |
| KR20230079499A (ko) | 2016-08-05 | 2023-06-07 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| WO2018187209A1 (en) * | 2017-04-03 | 2018-10-11 | Acceleron Pharma Inc. | Compositions and methods for treating spinal muscular atrophy |
| AU2018309187C1 (en) | 2017-08-04 | 2023-09-07 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| WO2019170930A1 (es) * | 2018-03-09 | 2019-09-12 | Universitat De Lleida | Tratamiento para la atrofia muscular espinal |
| WO2019204369A1 (en) * | 2018-04-17 | 2019-10-24 | Applied Stemcell, Inc. | Compositions and methods for treating spinal muscular atrophy |
| WO2020160291A2 (en) | 2019-01-30 | 2020-08-06 | Scholar Rock, Inc. | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF |
| JP2022521467A (ja) | 2019-02-05 | 2022-04-08 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| JP2022519323A (ja) | 2019-02-06 | 2022-03-22 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| US11918570B2 (en) | 2020-04-13 | 2024-03-05 | The Research Foundation For The State University Of New York | Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition |
| IL302132A (en) | 2020-10-26 | 2023-06-01 | Scholar Rock Inc | Use of anti-pro/latent myostatin antibody to treat spinal muscle wasting |
| IL309078A (en) | 2021-06-23 | 2024-02-01 | Scholar Rock Inc | A myostatin pathway inhibitor in combination with a GLP-1 pathway activator for use in the treatment of metabolic disorders |
| EP4370148A1 (en) | 2021-07-14 | 2024-05-22 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf beta1 and uses thereof |
| CN118055767A (zh) * | 2021-10-06 | 2024-05-17 | 豪夫迈·罗氏有限公司 | 新颖的组合施用 |
| WO2023215384A2 (en) * | 2022-05-04 | 2023-11-09 | Scholar Rock, Inc. | Use of myostatin inhibitor for treating spinal muscular atrophy |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| WO1994021681A1 (en) | 1993-03-19 | 1994-09-29 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| WO1996001845A1 (en) | 1994-07-08 | 1996-01-25 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-11 |
| US20030167492A1 (en) | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| PT2281843T (pt) | 2000-06-16 | 2017-01-02 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
| AU2011244851A1 (en) | 2000-07-27 | 2011-11-24 | The John Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| EP1300419B1 (en) | 2001-10-05 | 2007-06-13 | Affimed Therapeutics AG | Antibody of human origin for inhibiting thrombocyte aggregation |
| US8455627B2 (en) | 2001-10-05 | 2013-06-04 | Affimed Therapeutics, Ag | Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa |
| US20040044063A1 (en) | 2002-05-31 | 2004-03-04 | Brent Stockwell | SMA therapy and cell based assay for identifying therapies |
| TWI430810B (zh) | 2002-07-19 | 2014-03-21 | Abbott Lab S A | ＴＮＦα相關病症之治療 |
| US7572599B2 (en) | 2002-09-16 | 2009-08-11 | The Johns Hopkins University School Of Medicine | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| MXPA05005921A (es) | 2002-12-02 | 2005-10-19 | Abgenix Inc | Anticuerpos dirigidos a factor de necrosis tumoral y sus usos. |
| CN1902221A (zh) | 2003-12-31 | 2007-01-24 | 先灵-普劳有限公司 | 基于中和表位的生长增强疫苗 |
| US7456149B2 (en) | 2004-03-02 | 2008-11-25 | Acceleron Pharma, Inc. | ALK7 and myostatin inhibitors and uses thereof |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| KR20070026650A (ko) | 2004-05-27 | 2007-03-08 | 악셀레론 파마 인코포레이티드 | 케르베루스/코코 유도체 및 그의 용도 |
| WO2006017538A2 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| EP1851245B1 (en) | 2005-01-26 | 2012-10-10 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| US20060216279A1 (en) * | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
| EA201100642A1 (ru) | 2005-04-25 | 2011-12-30 | Пфайзер Инк. | Антитела к миостатину |
| JP5415071B2 (ja) | 2005-08-19 | 2014-02-12 | ワイス・エルエルシー | Ｇｄｆ−８に対するアンタゴニスト抗体ならびにａｌｓおよびその他のｇｄｆ−８関連障害の処置における使用 |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| WO2007061995A2 (en) | 2005-11-21 | 2007-05-31 | Novartis Ag | Biomarkers for statin-induced myopathy or rhabdomyolysis |
| US8097596B2 (en) | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
| WO2008030367A2 (en) * | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| CA2693178C (en) | 2006-11-29 | 2018-12-04 | Nationwide Children's Hospital, Inc. | Myostatin inhibition for enhancing muscle and/or improving muscle function |
| CN101663047B (zh) | 2007-02-23 | 2014-07-09 | 纽约哥伦比亚大学理事会 | 通过激活或阻断HLA-E/Qa-1限制性CD8+T细胞调控途径来治疗免疫疾病的方法 |
| WO2008119426A1 (en) | 2007-03-30 | 2008-10-09 | Merck Patent Gmbh | Birefingent layer with negative optical dispersion |
| CA2688725A1 (en) | 2007-04-12 | 2008-10-23 | Paratek Pharmaceuticals, Inc. | Methods for treating spinal muscular atrophy using tetracycline compounds |
| CA2688563A1 (en) | 2007-06-01 | 2008-12-11 | Biogen Idec Ma Inc. | Cripto binding molecules |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| AR074777A1 (es) | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | Proteinas de union a antigeno |
| KR101558642B1 (ko) | 2009-02-24 | 2015-10-12 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | Ｔｇｆ-베타 슈퍼패밀리의 설계자 리간드 |
| EA027071B1 (ru) | 2009-04-27 | 2017-06-30 | Новартис Аг | АНТИТЕЛО К ActRIIB И СОДЕРЖАЩАЯ ЕГО КОМПОЗИЦИЯ |
| EP3845239A1 (en) | 2009-06-08 | 2021-07-07 | Acceleron Pharma Inc. | Use of anti-actriib proteins for increasing thermogenic adipocytes |
| EP3511342B1 (en) | 2010-03-10 | 2024-01-17 | Genmab A/S | Monoclonal antibodies against c-met |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| NZ608206A (en) | 2010-08-16 | 2015-02-27 | Amgen Inc | Antibodies that bind myostatin, compositions and methods |
| WO2013071056A2 (en) | 2011-11-11 | 2013-05-16 | Duke University | Combination drug therapy for the treatment of solid tumors |
| US20130178454A1 (en) * | 2011-11-17 | 2013-07-11 | Shalender Bhasin | Combination of testosterone and ornithine decarboxylase (odc) inhibitors |
| WO2013148284A1 (en) | 2012-03-29 | 2013-10-03 | Genentech, Inc. | Antibodies that bind to a pcsk9 cleavage site and methods of use |
| WO2013165972A2 (en) | 2012-04-30 | 2013-11-07 | Cell Signaling Technology, Inc. | Anti-hepatitis b virus antibodies and use thereof |
| MY177331A (en) | 2012-06-15 | 2020-09-12 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
| JP2016500704A (ja) | 2012-11-06 | 2016-01-14 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | 細胞シグナル伝達を変調するための組成物及び方法 |
| BR112015027336A2 (pt) * | 2013-05-01 | 2017-09-26 | Genzyme Corp | composições e processos para tratamento de atrofia muscular espinhal |
| CA2911514A1 (en) | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| EP2853898B1 (en) | 2013-09-27 | 2017-01-04 | Medizinische Hochschule Hannover | Analysis of myostatin in serum |
| US10004814B2 (en) | 2013-11-11 | 2018-06-26 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety |
| WO2015195094A1 (en) | 2014-06-17 | 2015-12-23 | Ember Therapeutics, Inc. | Anti-activin and nati-myostatin antibodies and methods of using the same |
| WO2016073879A2 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related antibodies and uses thereof |
| JP6706617B2 (ja) * | 2014-11-06 | 2020-06-10 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | 抗プロ／潜在型−ミオスタチン抗体およびその使用 |
| EP3240804A4 (en) | 2014-12-19 | 2019-01-09 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE |
| WO2016168613A1 (en) * | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| MX2018003196A (es) | 2015-09-15 | 2019-05-16 | Scholar Rock Inc | Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos. |
| KR20180094110A (ko) | 2016-01-08 | 2018-08-22 | 스칼러 락, 인크. | 항-프로/잠재성 미오스타틴 항체 및 그의 사용 방법 |
| KR20230028813A (ko) | 2016-06-13 | 2023-03-02 | 스칼러 락, 인크. | 미오스타틴 억제제의 용도 및 조합 요법 |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
-
2017
- 2017-06-13 KR KR1020237005734A patent/KR20230028813A/ko active Application Filing
- 2017-06-13 HU HUE17732001A patent/HUE051480T2/hu unknown
- 2017-06-13 EP EP23157280.1A patent/EP4218804A3/en active Pending
- 2017-06-13 IL IL301468A patent/IL301468A/en unknown
- 2017-06-13 EP EP17732001.7A patent/EP3368069B1/en active Active
- 2017-06-13 US US16/308,007 patent/US10946036B2/en active Active
- 2017-06-13 KR KR1020197000822A patent/KR102271635B1/ko active IP Right Grant
- 2017-06-13 KR KR1020237042111A patent/KR20230169484A/ko active Application Filing
- 2017-06-13 PE PE2018003207A patent/PE20190205A1/es unknown
- 2017-06-13 SI SI201730485T patent/SI3368069T1/sl unknown
- 2017-06-13 EP EP20179533.3A patent/EP3785728A3/en active Pending
- 2017-06-13 RS RS20201327A patent/RS61090B1/sr unknown
- 2017-06-13 AU AU2017283546A patent/AU2017283546C1/en active Active
- 2017-06-13 MY MYPI2018002494A patent/MY185614A/en unknown
- 2017-06-13 JP JP2019517209A patent/JP6823167B2/ja active Active
- 2017-06-13 LT LTEP17732001.7T patent/LT3368069T/lt unknown
- 2017-06-13 ES ES17732001T patent/ES2830440T3/es active Active
- 2017-06-13 KR KR1020217019817A patent/KR20210082548A/ko not_active IP Right Cessation
- 2017-06-13 PT PT177320017T patent/PT3368069T/pt unknown
- 2017-06-13 WO PCT/US2017/037332 patent/WO2017218592A1/en active Application Filing
- 2017-06-13 DK DK17732001.7T patent/DK3368069T3/da active
-
2018
- 2018-12-05 IL IL263510A patent/IL263510A/en unknown
- 2018-12-13 CL CL2018003588A patent/CL2018003588A1/es unknown
-
2020
- 2020-07-27 AU AU2020210134A patent/AU2020210134B2/en active Active
- 2020-10-30 HR HRP20201764TT patent/HRP20201764T1/hr unknown
- 2020-11-03 CY CY20201101038T patent/CY1123678T1/el unknown
-
2021
- 2021-01-05 JP JP2021000367A patent/JP7161554B2/ja active Active
- 2021-02-03 US US17/248,700 patent/US20210283166A1/en active Pending
- 2021-11-04 AU AU2021261907A patent/AU2021261907A1/en active Pending
-
2022
- 2022-04-08 JP JP2022064360A patent/JP7344337B2/ja active Active
-
2023
- 2023-09-01 JP JP2023142275A patent/JP2023164920A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201764T1 (hr) | Upotreba inhibitora miostatina i kombinacijske terapije | |
| JP2019523295A5 (hr) | ||
| Kavanaugh et al. | Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo‐controlled study | |
| SI2780368T1 (en) | INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A | |
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| HRP20210393T1 (hr) | Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja | |
| HRP20212028T1 (hr) | Postupci za liječenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3 | |
| JP2011506483A5 (hr) | ||
| JP2012504634A5 (hr) | ||
| IL276896B1 (en) | Methods for treating Crohn's disease with a specific anti-IL23 antibody | |
| HRP20231338T1 (hr) | Kombinirana terapija hbv | |
| US20210009667A1 (en) | Anti-neurotensin long fragment antibodies and uses thereof | |
| HRP20230886T1 (hr) | Siguran i učinkovit postupak za liječenje ulcerativnog kolitisa s protutijelom anti-il12/il23 | |
| JP2020500152A5 (hr) | ||
| JP2014534956A5 (hr) | ||
| JP2021502349A5 (hr) | ||
| RU2018131123A (ru) | Антитела к tgf-бета2 | |
| RU2020133229A (ru) | Антитела к klk5 и способы применения | |
| DE112012000439T5 (de) | Stammzellfaktor-Inhibitor | |
| RU2020133768A (ru) | Способ лечения астмы или аллергического заболевания | |
| US20190016798A1 (en) | Anti-neurotensin antibodies and uses thereof | |
| JP2018535961A5 (hr) | ||
| SI2739311T1 (en) | Method for the treatment of bone defect defects | |
| JPWO2020059847A5 (hr) | ||
| JP2009538916A5 (hr) |